PolyPid Ltd. Ordinary Shares earnings per share and revenue
On Nov 12, 2025, PYPD reported earnings of -0.37 USD per share (EPS) for Q3 25, beating the estimate of -0.53 USD, resulting in a 30.57% surprise. Revenue reached --, compared to an expected --, with a 0.00% difference. The market reacted with a -0.27% price change (close before vs. close after earnings).
Looking ahead to Q4 25, 6 analysts forecast an EPS of -0.33 USD, with revenue projected to reach -- USD, implying an decrease of -10.81% EPS, and increase of 0.00% in Revenue from the last quarter.
Industry Peers’ Earnings
Industry Peers' Earnings displays EPS earnings data from companies in the same industry. Click on a card to view more details.
Takeda Pharmaceutical Company Limited - ADR
Report Date
Jan 30, 2026 For Q3 26
Estimate
$34.44
Actual
$65.64
Surprise
+90.61%
FAQ
What were PolyPid Ltd. Ordinary Shares's earnings and revenue for the latest quarter Q3 2025?
For Q3 2025, PolyPid Ltd. Ordinary Shares reported EPS of -$0.37, beating estimates by 30.57%, and revenue of $0.00, 0% as expectations.
How did the market react to PolyPid Ltd. Ordinary Shares's Q3 2025 earnings?
The stock price moved down -0.27%, changed from $3.76 before the earnings release to $3.75 the day after.
When is PolyPid Ltd. Ordinary Shares expected to report next?
The next earning report is scheduled for Feb 11, 2026.
What are the forecasts for PolyPid Ltd. Ordinary Shares's next earnings report?
Based on 6
analysts, PolyPid Ltd. Ordinary Shares is expected to report EPS of -$0.33 and revenue of -- for Q4 2025.